229 related articles for article (PubMed ID: 29651471)
1. Effect of sulfonamidoethylenediamine substituents in Ru
Chen F; Soldevila-Barreda JJ; Romero-Canelón I; Coverdale JPC; Song JI; Clarkson GJ; Kasparkova J; Habtemariam A; Brabec V; Wolny JA; Schünemann V; Sadler PJ
Dalton Trans; 2018 May; 47(21):7178-7189. PubMed ID: 29651471
[TBL] [Abstract][Full Text] [Related]
2. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
[TBL] [Abstract][Full Text] [Related]
3. Reversible pH-Responsive Behavior of Ruthenium(II) Arene Complexes with Tethered Carboxylate.
Martínez-Peña F; Infante-Tadeo S; Habtemariam A; Pizarro AM
Inorg Chem; 2018 May; 57(9):5657-5668. PubMed ID: 29688005
[TBL] [Abstract][Full Text] [Related]
4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
5. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
6. Half-sandwich rhodium(III) transfer hydrogenation catalysts: Reduction of NAD(+) and pyruvate, and antiproliferative activity.
Soldevila-Barreda JJ; Habtemariam A; Romero-Canelón I; Sadler PJ
J Inorg Biochem; 2015 Dec; 153():322-333. PubMed ID: 26601938
[TBL] [Abstract][Full Text] [Related]
7. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
8.
Gopalakrishnan D; Saravanan S; Merckx R; Madan Kumar A; Khamrang T; Velusamy M; Vasanth K; Sunitha S; Hoogenboom R; Maji S; Ganeshpandian M
Dalton Trans; 2021 Jun; 50(23):8232-8242. PubMed ID: 34037018
[TBL] [Abstract][Full Text] [Related]
9. Catalysis of regioselective reduction of NAD+ by ruthenium(II) arene complexes under biologically relevant conditions.
Yan YK; Melchart M; Habtemariam A; Peacock AF; Sadler PJ
J Biol Inorg Chem; 2006 Jun; 11(4):483-8. PubMed ID: 16604356
[TBL] [Abstract][Full Text] [Related]
10. The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts.
Fu Y; Sanchez-Cano C; Soni R; Romero-Canelon I; Hearn JM; Liu Z; Wills M; Sadler PJ
Dalton Trans; 2016 May; 45(20):8367-78. PubMed ID: 27109147
[TBL] [Abstract][Full Text] [Related]
11. Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design.
Soldevila-Barreda JJ; Romero-Canelón I; Habtemariam A; Sadler PJ
Nat Commun; 2015 Mar; 6():6582. PubMed ID: 25791197
[TBL] [Abstract][Full Text] [Related]
12. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
13. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
14. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
15. Highly cytotoxic trithiophenolatodiruthenium complexes of the type [(η6-p-MeC6H4Pri)2Ru2(SC6H4-p-X)3]+: synthesis, molecular structure, electrochemistry, cytotoxicity, and glutathione oxidation potential.
Giannini F; Furrer J; Ibao AF; Süss-Fink G; Therrien B; Zava O; Baquie M; Dyson PJ; Stěpnička P
J Biol Inorg Chem; 2012 Aug; 17(6):951-60. PubMed ID: 22707191
[TBL] [Abstract][Full Text] [Related]
16. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
17. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
18. Half-sandwich organometallic Ru and Rh complexes of (N,N) donor compounds: effect of ligand methylation on solution speciation and anticancer activity.
Mészáros JP; Pape VFS; Szakács G; Németi G; Dénes M; Holczbauer T; May NV; Enyedy ÉA
Dalton Trans; 2021 Jun; 50(23):8218-8231. PubMed ID: 34032247
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
20. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
